Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abt-925. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 20/20 | 0.62 |
| ▸ | DRD2 | P14416 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-925 SCHEMBL1078007 | 1.00 | DRD2 (0.62) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL7658673 | 0.97 | DRD2 (0.59) | DRD2DRD3 | |
| Abt-925 SCHEMBL1043144 | 0.93 | DRD2 (0.67) | DRD2DRD3 | |
| Abt-925 SCHEMBL29462266 | 0.93 | DRD2 (0.67) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL4397753 | 0.87 | DRD2 (0.52) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL4397762 | 0.87 | DRD2 (0.52) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL1044942 | 0.87 | DRD2 (0.46) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL27571134 | 0.87 | DRD2 (0.46) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL4392108 | 0.86 | DRD2 (0.49) | DRD2DRD3 | |
| Fumaric Acid SCHEMBL4392115 | 0.86 | DRD2 (0.49) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | claimed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | claimed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | claimed |
| EP-1176963-B1 | USE OF DOPAMINE D 3 RECEPTOR ANTAGONISTS FOR PRODUCING MEDICAMENTS FOR TREATING KIDNEY DISORDERS | ABBOTT GMBH & CO KG (DE) | 2004-12-15 | — | — | EP | claimed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| EP-1003728-B1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | ABBOTT GMBH & CO KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-1003728-B1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | ABBOTT GMBH & CO KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2272833-A1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyridin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | disclosed |
| EP-1176963-B1 | USE OF DOPAMINE D 3 RECEPTOR ANTAGONISTS FOR PRODUCING MEDICAMENTS FOR TREATING KIDNEY DISORDERS | ABBOTT GMBH & CO KG (DE) | 2004-12-15 | — | — | EP | disclosed |
| US-6486162-B2 | FOR THERAPY OF DISORDER OF THE CENTRAL NERVOUS SYSTEM WHICH RESPONDS TO DOPAMINE D3 LIGANDS SUCH AS SCHIZOPHRENIA, DEPRESSION, NEUROSES AND PSYCHOSES | ABBOTT LABORATORIES | 2002-11-26 | — | — | US | disclosed |
| US-20020143179-A1 | 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-10-03 | — | — | US | disclosed |
| EP-1176963-A2 | USE OF DOPAMINE D 3? RECEPTOR LIGANDS FOR PRODUCING MEDICAMENTS FOR TREATING KIDNEY DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000067847-A2 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR PRODUCING MEDICAMENTS FOR TREATING KIDNEY DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143179-A1 | 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | SLC6A3, DRD2, DRD3 | DRD3 3/4885DRD2 2/4885 |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | SLC6A3, DRD3, DRD2 | DRD3 2/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.